Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesSafety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis
Antimicrobial Agents and Chemotherapy, 06/29/09
Spellberg B et al. - Deferasirox was administered for an average of 14 days at 5 to 20 mg/kg of body weight/day. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Drugs for preventing malaria in travellers
Cochrane Reviews, 10/22/09
Comparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal Dialysis
Advances in Peritoneal Dialysis, 10/20/09
Empirical Antimicrobial Therapy for Bloodstream Infection Due to Methicillin-Resistant Staphylococcus aureus: No Better than a Coin Toss
Infection Control and Hospital Epidemiology, 10/14/09
Sponsor
Article Search
Sponsor